Work

Real-world use of olaparib in US veterans with metastatic castration-resistant prostate cancer: Treatment patterns and outcomes.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.5071

Authors: Christelle McFarland, Lin Gu, Joshua Parrish, Anna M. Hoffmeyer, Jaruda Ithishupalap, Jean Hai Ein Yong, Chinelo Orji, Leah Catherine Rider, Nina Yeh, Andrew Lloyd, Thomas Polascik, Stephen J. Freedland

Institutions: Durham VA Health Care System, Durham VA Medical Center, Duke University, Duke Cancer Institute, AstraZeneca (Canada), Merck & Co., Inc., Rahway, NJ, USA (United States), AstraZeneca (United States), AstraZeneca (United Kingdom), Cedars-Sinai Medical Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162490906

Cites:

Cited by:

Related to: